Endonovo Therapeutics (ENDV) Assets Average (2016 - 2023)
Endonovo Therapeutics has reported Assets Average over the past 11 years, most recently at $915292.5 for Q3 2023.
- Quarterly results put Assets Average at $915292.5 for Q3 2023, down 39.9% from a year ago — trailing twelve months through Sep 2023 was $915292.5 (down 39.9% YoY), and the annual figure for FY2022 was $1.6 million, down 28.73%.
- Assets Average for Q3 2023 was $915292.5 at Endonovo Therapeutics, down from $1.1 million in the prior quarter.
- Over the last five years, Assets Average for ENDV hit a ceiling of $4.0 million in Q1 2019 and a floor of $915292.5 in Q3 2023.
- Median Assets Average over the past 5 years was $2.4 million (2021), compared with a mean of $2.4 million.
- Biggest five-year swings in Assets Average: skyrocketed 69.11% in 2019 and later tumbled 39.9% in 2023.
- Endonovo Therapeutics' Assets Average stood at $3.3 million in 2019, then dropped by 20.17% to $2.7 million in 2020, then fell by 22.39% to $2.1 million in 2021, then tumbled by 34.06% to $1.4 million in 2022, then plummeted by 33.01% to $915292.5 in 2023.
- The last three reported values for Assets Average were $915292.5 (Q3 2023), $1.1 million (Q2 2023), and $1.2 million (Q1 2023) per Business Quant data.